Key Insights

Highlights

Treatment Research

3 treatments under study, led by Cytarabine

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT02255162Phase 1Terminated

Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML

Showing all 1 trials

Research Network

Common Treatments

  • Cytarabine1
  • Hlamismatched Stemcell Microtransplantation1
  • Lenalidomide1

Active Sponsors

  • Massachusetts General Hospital1
  • Celgene Corporation1

Top Investigators

Related Conditions

  • Acute Nonlymphocytic Leukemia1
  • Acute Myeloid Leukemia Aml1
  • Acute Myelocytic Leukemia1
  • Acute Myelogenous Leukemia1

Activity Timeline